Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will participate in the Sachs Associates 5th Annual Neuroscience Innovation Forum. At the conference, Dr Stamler will be featured on a panel entitled, “Progress ...
Author: Alterity Therapeutics
Study demonstrates reduction of α-synuclein aggregation and preservation of neurons Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that data in an animal model of Multiple System Atrophy (MSA) were published in the Journal of Parkinson’s Disease. MSA is ...
Highlights: NZ’s regulator Medsafe authorizes Phase 2 clinical trial for ATH434; more jurisdictions to follow New poster presentation and publications provide further evidence of potential of ATH434 to treat neurodegenerative diseases New US composition of matter patent secures exclusivity for a new class of compounds targeting Parkinson’s and Alzheimer’s diseases Active investor relations program in ...
All stakeholders of Alterity Therapeutics, are invited to register to view the Company’s presentation at the H.C. Wainwright BIOCONNECT Virtual Conference. Link to registration: https://journey.ct.events/view/21ae761a-b573-416e-b956-825d1f5a86b3 Alterity will begin its presentation on Monday 10/1/21 at 7:00 AM (Eastern Standard Time; 11:30pm AEST). A recorded copy of the webinar will be made available following the event.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the United States Patent and Trademark Office (USPTO) has granted a new patent (No. 11,155,547) to Alterity. The composition of matter patent, entitled “Compounds for and Methods of Treating Diseases”, underwent ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022. The presentation will be accessible on the Alterity website under News on Monday, January ...
Initiation of Phase 2 Clinical Trial Expected in CY Q1 2022 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has authorized Alterity’s Phase 2 clinical trial for ATH434 ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced that David Stamler, M.D., Chief Executive Officer will participate in two upcoming virtual investor events: MST Financial Lifesciences & Biotech Fourm Wednesday, November 24th at 5:20 p.m. PST (U.S.) / Thursday, ...
AGM 2021 Presentation
I am pleased to present my Chairman’s address at this year’s Annual General Meeting. For the second year in a row, we do this under unique circumstances, and we appreciate the involvement of our shareholders and our corporate partners in today’s virtual setting. FY 21 was a significant year for Alterity and for me personally ...